5,344
Views
7
CrossRef citations to date
0
Altmetric
Hematology

Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma

, , , , , ORCID Icon, , , , , ORCID Icon, ORCID Icon, , , & ORCID Icon show all
Pages 81-89 | Received 30 Aug 2022, Accepted 18 Oct 2022, Published online: 15 Nov 2022

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.